<DOC>
	<DOCNO>NCT02106455</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy sodium risedronate tablet ( Benet 17.5 mg Tablets ) administer daily ( one tablet per dose ) patient osseous Paget 's disease 48 week baseline daily medical practice .</brief_summary>
	<brief_title>Sodium Risedronate Tablets - Special Drug Use Surveillance Patients With Osseous Paget 's Disease ( All-case Surveillance ) -48-week Surveillance âˆ’</brief_title>
	<detailed_description>This special drug use surveillance design evaluate safety efficacy sodium risedronate tablet ( Benet 17.5 mg Tablets ) administer daily ( one tablet per dose ) patient osseous Paget 's disease daily medical practice . The usual dosage adult 17.5 mg sodium risedronate administer orally sufficient volume ( approximately 180 mL ) water daily wake 8 consecutive week . For least 30 minute administration , patient avoid lie supine position take food , drink ( except water ) oral drug .</detailed_description>
	<mesh_term>Osteitis Deformans</mesh_term>
	<mesh_term>Risedronate Sodium</mesh_term>
	<mesh_term>Etidronic Acid</mesh_term>
	<criteria>Osseous Paget 's disease patient treat sodium risedronate tablet ( Benet 17.5 mg Tablets )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Pharmacological theapy</keyword>
</DOC>